Recombinant protein FGF2-STAB® is a stabilized growth factor developed by Masaryk University in collaboration with its spin-off company Enantis. FGF2-STAB® is a molecule improved by protein engineering and has a prolonged biological effect compared to the native form of FGF2. At 37 °C, this stable molecule is active for more than thirty days instead of a few hours, facilitating its use as a reagent in cell culture. FGF2-STAB® also has potential in the treatment of a number of diseases – particularly in the field of regenerative medicine. When applied to a wound, this protein promotes the process of angiogenesis and vascularization, the proliferation and migration of fibroblasts, and increases the motility of keratinocytes during re-epithelialization. It also has the ability to stimulate collagenase production, reduce scar formation and suppress the inflammatory reaction. The aim of the CZECRIN and ENANTIS collaboration is to move FGF2-STAB® towards clinical applications, as a potential product into the clinical testing phases and, as a result, especially closer to patients with selected indications.
